
James R Rogers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1114892/publications.pdf Version: 2024-02-01



IAMES P ROCERS

#	Article	IF	CITATIONS
1	Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety. Journal of Biomedical Informatics, 2022, 127, 104032.	4.3	1
2	Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 144-154.	4.4	33
3	Al uses patient data to optimize selection of eligibility criteria for clinical trials. Nature, 2021, 592, 512-513.	27.8	7
4	Comparison of Clinical Characteristics Between Clinical Trial Participants and Nonparticipants Using Electronic Health Record Data. JAMA Network Open, 2021, 4, e214732.	5.9	18
5	Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method. Journal of Biomedical Informatics, 2021, 119, 103822.	4.3	8
6	Published models that predict hospital readmission: a critical appraisal. BMJ Open, 2021, 11, e044964.	1.9	8
7	A Framework for Systematic Assessment of Clinical Trial Population Representativeness Using Electronic Health Records Data. Applied Clinical Informatics, 2021, 12, 816-825.	1.7	3
8	Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 14-22.	4.4	19
9	Understanding the nature and scope of clinical research commentaries in PubMed. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 449-456.	4.4	10
10	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Safety, 2019, 42, 85-93.	3.2	5
11	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine, 2019, 16, e1002763.	8.4	55
12	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. BMJ Quality and Safety, 2019, 28, 835-842.	3.7	13
13	A Data Element-Function Conceptual Model for Data Quality Checks. EGEMS (Washington, DC), 2019, 7, 17.	2.0	4
14	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Seminars in Arthritis and Rheumatism, 2018, 48, 399-405.	3.4	37
15	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ: British Medical Journal, 2018, 361, k1180.	2.3	27
16	The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. American Heart Journal, 2018, 197, 153-162.	2.7	26
17	Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. Journal of Comparative Effectiveness Research, 2018, 7, 1073-1082.	1.4	1
18	Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. PLoS ONE, 2018, 13, e0192788.	2.5	4

JAMES R ROGERS

#	Article	IF	CITATIONS
19	Use of electronic healthcare records to identify complex patients with atrial fibrillation for targeted intervention. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 339-344.	4.4	31
20	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multiâ€Database Cohort Study. Arthritis and Rheumatology, 2017, 69, 1154-1164.	5.6	160
21	Survey of Living Organ Donors' Experience and Directions for Process Improvement. Progress in Transplantation, 2017, 27, 232-239.	0.7	6
22	Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Medical Care, 2017, 55, 1046-1051.	2.4	67
23	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. Value in Health, 2015, 18, 1063-1069.	0.3	3
24	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. Value in Health, 2015, 18, 1057-1062.	0.3	3
25	Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis. PLoS ONE, 2015, 10, e0122646.	2.5	94